The RApid Switch From 1st Generation Somatostatin Analogues to PaSireOtiDe In Acromegaly
ConditionAcromegaly
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorIRCCS San Raffaele
About this trial
This is an observational, retrospective, national multicenter study aimed to evaluate the impact and efficacy of Time To Switch (TTS) from first-line to second-line medical therapy in Acromegaly.
Eligibility criteria
Qualifiers
Adult men and women (age ≥ 18 years) affected by acromegaly, including those of childbearing age
Patients inadequately controlled with first generation somatostatin analogues (GH ≥1 μg/L and IGF-1 >1.3×ULN)
Second line medical treatment (Pasireotide; Pegvisomant only; combination Pegvisomant + 1st generation SSA) after use of first-line medical treatment
At least 12 months of follow up during 2nd line therapy
Disqualifiers
age ≤18 years
Pregnant and/or breastfeeding women
Patients unable to understand and sign the Informed Consent
Trial design
Treatments tested in this trial
- Not listed
Trial groups
No trial groups listed
Sponsors and collaborators
IRCCS San Raffaele
Lead sponsor
University of Turin, Italy
Collaborator
University of Padova
Collaborator
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Collaborator
Source ClinicalTrials.gov